Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00222482. We help you review the study, but cannot decide medical eligibility.
CompletedNCT00222482
A and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder
This study is completed. It is testing Depakote ER for Borderline Personality Disorder.
Personality disorders, Borderline personalityDrugFrom 21 Years to 55 Years
Understand this study
Who could participate?
Listed age limits: 21 years to 55 years.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateMarch 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 15
- Sponsor
- University of Minnesota
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Not clearly listed
- Age range
- From 21 Years to 55 Years
- Official registry ID
- NCT00222482
- Official title
- A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder
Recruitment & locations
CompletedLocations not listed
Compensation and expense reimbursement have not been verified for this summary.
Registry details
Registry conditions (original wording)
Borderline Personality Disorder
Questions about this study
Who is behind this study?
The study sponsor is University of Minnesota, a university.
Does this study involve medication?
Yes. The study involves medication, including Depakote ER.
Who can participate?
Listed age limits: 21 years to 55 years.
Is this study still recruiting?
The registry lists this study as completed.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01243658
"The Effects of Oxytocin on people with Borderline Personality Disorder"
This study is completed. It focuses on personality disorders and currently lists study information in Germany.
CompletedNCT02507206
A D1 Agonist For Working Memory
This study is completed. It focuses on personality disorders and currently lists study information in the United States.
CompletedEUCTR 2020-003469-20
A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.